scPharmaceuticals Inc. Files 8-K: Key Events Unfold
| Field | Detail |
|---|---|
| Company | Scpharmaceuticals Inc. |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | high |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.0001, $5.35, $1.00 |
| Sentiment | mixed |
Sentiment: mixed
Topics: corporate-action, delisting-risk, management-change, asset-disposition
Related Tickers: SCPH
TL;DR
SCPH files 8-K: Termination, acquisition, delisting notice, change of control, exec changes - big shakeup!
AI Summary
On October 7, 2025, scPharmaceuticals Inc. filed an 8-K detailing several significant events. These include the termination of a material definitive agreement, the completion of an acquisition or disposition of assets, and notice of potential delisting or failure to meet listing standards. The company also reported material modifications to security holder rights and a change in control of the registrant. Additionally, there were changes in directors or officers and updates regarding compensatory arrangements.
Why It Matters
This 8-K filing signals significant corporate restructuring and potential financial distress for scPharmaceuticals Inc., which could impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — The filing indicates multiple critical events including termination of agreements, potential delisting, and changes in control, suggesting significant operational and financial instability.
Key Players & Entities
- scPharmaceuticals Inc. (company) — Registrant
- October 7, 2025 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement was terminated by scPharmaceuticals Inc.?
The filing does not specify the exact material definitive agreement that was terminated, only that such a termination occurred on or before October 7, 2025.
What was the nature of the acquisition or disposition of assets by scPharmaceuticals Inc.?
The filing indicates the completion of an acquisition or disposition of assets, but does not provide details on the specific assets involved or the transaction's nature.
What are the reasons for the notice of delisting or failure to satisfy a continued listing rule for scPharmaceuticals Inc.?
The filing states there was a notice of delisting or failure to satisfy a continued listing rule, but does not elaborate on the specific rule or standard not met.
What material modifications were made to the rights of scPharmaceuticals Inc. security holders?
The filing reports material modifications to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.
What changes occurred regarding the directors or officers of scPharmaceuticals Inc.?
The filing mentions the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements, but specific names and details are not provided in this excerpt.
Filing Stats: 2,794 words · 11 min read · ~9 pages · Grade level 13.4 · Accepted 2025-10-07 09:18:44
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SCPH The Nasdaq Global Se
- $5.35 — Shares "), at a price per Share of (i) $5.35 in cash (the " Cash Amount "), without
- $1.00 — ayments of up to an aggregate amount of $1.00 per CVR in cash, without interest, subj
Filing Documents
- d20686d8k.htm (8-K) — 47KB
- d20686dex31.htm (EX-3.1) — 6KB
- d20686dex32.htm (EX-3.2) — 90KB
- 0001193125-25-232754.txt ( ) — 291KB
- scph-20251007.xsd (EX-101.SCH) — 3KB
- scph-20251007_lab.xml (EX-101.LAB) — 18KB
- scph-20251007_pre.xml (EX-101.PRE) — 11KB
- d20686d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description of Exhibit 2.1 Agreement and Plan of Merger, dated as of August 24, 2025, by and among scPharmaceuticals Inc., Seacoast Merger Sub, Inc. and MannKind Corporation (incorporated by reference to Exhibit 2.1 on the Current Report on Form 8-K, filed on August 25, 2025).* 3.1 Third Amended and Restated Certificate of Incorporation of scPharmaceuticals Inc. (filed herewith). 3.2 Second Amended and Restated Bylaws of scPharmaceuticals Inc. (filed herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain annexes and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted annexes and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any annexes or schedules so furnished.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 7, 2025 scPharmaceuticals Inc. By: /s/ David Thomson Name: David Thomson Title: Secretary